Press release no 6 -2015
Targovax announces presentation of data from the ongoing phase I/II clinical study of the RAS-specific therapeutic cancer vaccine TG01 in resected pancreatic cancer at ASCO 2015 in Chicago.
Targovax Interim Report for Q1 2015 is now available for download.Read more
Targovax will participate at Bio-International, Philadelphia, June 14-18, 2015.Read more
Targovax will participate at the ASCO Annual Meeting (American Society of Clinical Oncology) in Chicago, June 1-3 2015.Read more
Press release no 5 -2015
Targovax has appointed Peter Skorpil as Head of Business Development, effective from April 8th, 2015. Peter Skorpil, PhD, MBA, VP Business Development, has extensive experience in licensing, commercial assessments, business intelligence and partnering.
Press release no 4 - 2015
TG01, a novel peptide vaccine against cancer specific RAS mutations, is tested in combination with gemcitabine as adjuvant treatment in resected pancreatic cancer.